Patients who were counseled on heart medications and lifestyle modifications by specially trained nurses were 30% less likely to experience cardiovascular death, heart attack or stroke five years after being hospitalized for acute coronary syndrome (ACS) compared with those who received standard care, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available medical therapy plus a minimally invasive procedure using a clip to repair the valve were 28% less likely to be hospitalized for recurrent heart failure than similar patients who were initially randomly assigned to medical therapy alone. The study was presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial’s prespecified goal of 25% to show non-inferiority, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

Patients with narrowing of at least 50% in three major coronary arteries did equally well when treated with a minimally invasive stent placement guided either by ultrasound-based imaging or by a novel, artificial-intelligence-powered (AI), non-invasive imaging technique derived from angiography, researchers reported at the American College of Cardiology’s Annual Scientific Session (ACC.25).  

About The Study: Among patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure randomized clinical trial, higher proportions of cardiovascular and overall mortality in those with ejection fraction less than 50% were related principally to higher proportions of sudden death. A clear treatment effect of finerenone on cardiovascular or cause-specific mortality was not identified, although the trial was likely underpowered for these outcomes.

A program that delivered in-home visits from a trained paramedic team to people with heart failure did not significantly reduce 30-day hospital readmissions or improve health status compared with standard follow-up phone calls, according to research presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).